61 results
8-K
PHASQ
PhaseBio Pharmaceuticals Inc
15 Nov 21
Regulation FD Disclosure
11:32am
had no apparent effect on ticagrelor reversal as measured by VerifyNow or on achievement of effective hemostasis.
Thrombotic Events and Assessment … none resulted in death, and none were considered by investigators to be related to treatment with bentracimab. An assessment of whether bentracimab
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
15 Nov 21
Regulation FD Disclosure
11:32am
reversal as measured by VerifyNow or on achievement of effective hemostasis.
Thrombotic Events and Assessment of Potential Prothrombotic Rebound
Eight … considered by investigators to be related to treatment with bentracimab. An assessment of whether bentracimab induced potentially prothrombotic changes
DRS
EX-10.9
PHASQ
PhaseBio Pharmaceuticals Inc
27 Jul 18
Draft registration statement
12:00am
in an amount up to 30% of your base salary based on the Company’s assessment of your individual performance and overall Company performance. In order
S-1
EX-10.8
PHASQ
PhaseBio Pharmaceuticals Inc
21 Sep 18
IPO registration
4:15pm
in an amount up to 30% of your base salary based on the Company’s assessment of your individual performance and overall Company performance. In order
DRS
EX-10.8
PHASQ
PhaseBio Pharmaceuticals Inc
27 Jul 18
Draft registration statement
12:00am
in an amount up to 30% of your base salary based on the Company’s assessment of your individual performance and overall Company performance. In order
S-1
EX-10.9
kw12miq3wuror
21 Sep 18
IPO registration
4:15pm
8-K
EX-99.3
lokusly
14 Aug 19
Regulation FD Disclosure
12:00am
8-K
EX-99.1
jcv5ah xnv
23 Oct 20
PhaseBio Provides Pemziviptadil (PB1046) Program Update
8:20am
8-K
EX-99.1
ev4lvi1n0mq20j9ht7w7
12 Nov 20
PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results
4:12pm
CORRESP
83gca
28 Sep 18
Correspondence with SEC
12:00am
DEF 14A
2db1gtsc5 1o41zj86tv
5 Apr 19
Definitive proxy
4:05pm
8-K
EX-99.2
mer6aziqrn1
15 Mar 21
PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
8:10am
8-K
EX-1.1
8j3azzp
19 Mar 21
PhaseBio Announces Pricing of Public Offering of Common Stock
4:08pm
S-3
EX-1.2
4pvcf0b l6h0cytx
27 Dec 19
Shelf registration
5:28pm